(Q37481436)

20 August 2017

1 reference

title

Thiazolides: a new class of antiviral drugs (English)

1 reference

20 August 2017

author name string

Jean-François Rossignol

series ordinal

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

20 August 2017

published in

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

667-674

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

20 August 2017

1 reference

Anthelmintics. Current concepts in the treatment of helminthic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Nitazoxanide: a new thiazolide antiparasitic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Is metronidazole carcinogenic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Tauroursodeoxycholic acid: relieving the pathogenesis of HFE C282Y hereditary hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902988487

10.1517/17425250902988487

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference